Related Experiment Video

Updated: Jun 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer

Masuo Yamaoka1, Takahito Hara, Masami Kusaka

  • 1Takeda Pharmaceutical Company Limited, Tsukuba, Japan. Yamaoka_Masuo@takeda.co.jp

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 22, 2010
PubMed

Insights

Prostate cancer often becomes resistant to hormone therapy due to intracrine androgen production. Studying circulating tumor cells may reveal resistance mechanisms and identify patients benefiting from new therapies targeting 17,20-lyase.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Prostate cancer is a leading cause of cancer death in males.
  • Initial hormone therapy for prostate cancer frequently leads to castration-resistant prostate cancer (CRPC).
  • Intracrine androgen synthesis is a significant mechanism driving CRPC progression by reactivating androgen receptor signaling.

Purpose of the Study:

  • To explore the role of intracrine androgen synthesis in castration resistance.
  • To investigate the potential of 17,20-lyase inhibitors and second-generation anti-androgens for CRPC treatment.
  • To highlight the importance of circulating tumor cells in understanding CRPC and guiding therapy.

Main Methods:

  • Review of proposed mechanisms for castration resistance.
  • Discussion of the role of 17,20-lyase in androgen synthesis.
  • Emphasis on the potential utility of circulating tumor cell analysis.

Main Results:

  • Intracrine androgen production is a key factor in CRPC development.
  • 17,20-lyase inhibitors and novel anti-androgens show promise but face emerging resistance.
  • Circulating tumor cells offer insights into therapeutic response and resistance.

Conclusions:

  • Targeting intracrine androgen synthesis is crucial for managing CRPC.
  • Further research into 17,20-lyase inhibitors and anti-androgens is warranted.
  • Circulating tumor cell analysis is vital for personalized treatment strategies in CRPC.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...